Enoch, Jamie http://orcid.org/0000-0002-4614-6676
Ghulakhszian, Arevik http://orcid.org/0000-0002-5503-3892
Sekhon, Mandeep
Crabb, David P. http://orcid.org/0000-0001-8754-3902
Taylor, Deanna J. http://orcid.org/0000-0001-8261-5225
Dinah, Christiana http://orcid.org/0000-0002-0815-4771
Article History
Received: 6 January 2023
Revised: 11 April 2023
Accepted: 26 April 2023
First Online: 11 May 2023
Competing interests
: Jamie Enoch, Arevik Ghulakhszian and Mandeep Sekhon declare that they have no competing interests. David P Crabb reports grants from Roche, grants and personal fees from Santen, grants and personal fees from Apellis, grants from Allergan, personal fees from Thea, personal fees from Bayer and personal fees from Centervue, outside the submitted work. DPC receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant 116076 (Macustar). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA). The communication reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein. Deanna J Taylor holds a research grant from Apellis. Christiana Dinah has served on advisory boards for Novartis, AbbVie, Ora Clinical, Roche and Apellis. CD is on the scientific advisory board for Ora Clinical, has received speaker fees from Roche and Novartis and holds a research grant from Apellis.
Free to read: This content has been made available to all.